Mon, March 9, 2020
Sun, March 8, 2020
Fri, March 6, 2020
Thu, March 5, 2020

Keay Nakae Upgraded (ABUS) to Strong Buy and Increased Target to $5 on, Mar 6th, 2020

Keay Nakae of Chardan Capital, Upgraded "Arbutus Biopharma Corporation" (ABUS) to Strong Buy and Increased Target from $1.5 to $5 on, Mar 6th, 2020.

Keay has made no other calls on ABUS in the last 4 months.



There are 2 other peers that have a rating on ABUS. Out of the 2 peers that are also analyzing ABUS, 0 agree with Keay's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Keay


  • Madhu Kumar of "Baird" Initiated at Buy and Held Target at $8 on, Thursday, February 20th, 2020
  • Liisa Bayko of "JMP Securities" Upgraded from Hold to Buy and Held Target at $10 on, Wednesday, February 5th, 2020